Leo Pharma brings in old friends and new blood for eczema treatment launch

While Leo Pharma waits for a response to its approval application for eczema treatment Adtralza in the US, it is launching the treatment in the EU, where Head of Europe Monica Shaw can put the experience from launching psoriaris treatment Kyntheum to good use.

Monica Shaw, an Executive Vice President, Head of Europe, Canada and Australia at Leo Pharma | Photo: Leo Pharma / PR

Leo Pharma is making the most of its EU approval for eczema treatment Adtralza (tralokinumab) coming in two weeks earlier than expected.

Monica Shaw, an Executive Vice President at Leo Pharma who was appointed Head of Europe a little over a year ago, is responsible for the launch of the treatment in Europe, which will also be the first launch of the drug following a rejection of the drug by the FDA earlier in the year.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs